CurrentCignaPolicy IP0639

Xeomin (incobotulinumtoxinA) coverage

Defines medical necessity, prior authorization, dosing limits, approved indications, and coding for Xeomin (incobotulinumtoxinA) for Cigna-administered plans. Applies to requests for benefit coverage (excludes cosmetic use).

Policy Summary

PayerCigna

PolicyXeomin (incobotulinumtoxinA) coverage

Policy CodePolicy IP0639

Change TypeNew and revised (dosing update)

Effective Date

Next Review Date

Key ActionObtain prior authorization and submit required clinical documentation demonstrating the indication and dosing criteria are met before requesting coverage.

SourceLink

POLICY UPDATE CHANGES

New policy created for Xeomin (incobotulinumtoxinA).

Cervical dystonia maximum dosing updated from 120 units to 240 units (initial dose still not to exceed 120 units).

Policy template updated (administrative).

4FDA‑approved indications listed

Prior AuthAuthorization status

120–400Dose ranges across indications (max per indication)

Cosmetic uses excludedNot covered examples

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

General policy statement

Xeomin is medically necessary when ONE of the following FDA‑approved indication criteria are met. Prior Authorization is required.

label

Dosing limits by indication

Approvals include dosing maximums and minimum intervals between administrations.

ref

title": "Dosing limits by indication"

label

Not covered

Uses considered not medically necessary (examples):

ALL of the following

Cosmetic use (e.g., facial rhytides, frown lines, glabellar wrinkling, horizontal neck rhytides, mid/lower face and neck rejuvenation, platysmal bands, periorbital rejuvenation)
Any other use not listed in the FDA-approved indications in this policy

Relevant CPT / HCPCS Codes

Blepharospasm CPT/HCPCSmixedCovered

64612	Chemodenervation of muscle(s); muscle(s) innervated by facial nerve, unilateral (eg, for blepharospasm, hemifacial spasm)
J0588	Injection, IncobotulinumtoxinA, 1 unit

Cervical dystonia CPT/HCPCSmixedCovered

64616	Chemodenervation of muscle(s); neck muscle(s), excluding muscles of the larynx, unilateral (eg, for cervical dystonia, spasmodic torticollis)
J0588	Injection, IncobotulinumtoxinA, 1 unit

Sialorrhea CPT/HCPCSmixedCovered

64611	Chemodenervation of parotid and submandibular salivary glands, bilateral
J0588	Injection, IncobotulinumtoxinA, 1 unit

Upper limb spasticity CPT/HCPCSmixedCovered

64642	Chemodenervation of one extremity; 1-4 muscle(s)
64643	Chemodenervation of one extremity; each additional extremity, 1-4 muscle(s)
64644	Chemodenervation of one extremity; 5 or more muscles
64645	Chemodenervation of one extremity; each additional extremity, 5 or more muscles
64646	Chemodenervation of trunk muscle(s); 1-5 muscle(s)
64647	Chemodenervation of trunk muscle(s); 6 or more muscles
J0588	Injection, IncobotulinumtoxinA, 1 unit

What Providers Must Do

Prior Authorization

Prior authorization required for Xeomin

Prior Authorization is required for benefit coverage of Xeomin; approvals are recommended only when the patient meets the policy Criteria and Dosing. Extended approvals may be granted if the patient continues to meet the Criteria and Dosing; all approvals are provided for the duration noted in the policy.

Documentation Required

Documentation required for blepharospasm and cervical dystonia

Clinical documentation (e.g., chart notes) is required where indicated in the criteria: for blepharospasm include evidence of intermittent or sustained closure of the eyelids from involuntary orbicularis oculi contractions; for cervical dystonia include the diagnosis plus documentation of sustained head torsion and/or tilt with limited neck range of motion.

Blepharospasm: documentation of involuntary orbicularis oculi contractions is required.
Cervical dystonia: documentation of diagnosis and sustained head torsion/tilt with limited neck range of motion is required.

Note

Doses outside policy reviewed case‑by‑case

Requests for doses outside the dosing limits established in this policy will be reviewed on a case‑by‑case basis by a clinician (Medical Director or Pharmacist).

Clinician review may permit exceptions when justified; refer to policy dosing tables for standard maximums and intervals.

Denial Risk

Cosmetic and non‑listed indications are not covered

Use of Xeomin for cosmetic purposes or for indications not listed as covered in this policy is considered not medically necessary and is not recommended for coverage.

Examples of excluded cosmetic uses include facial rhytides, frown lines, glabellar wrinkling, horizontal neck rhytides, mid/lower face and neck rejuvenation, platysmal bands, and periorbital rejuvenation.

Quick Reference: Age, Dose, and Interval Limits

Key thresholds and dosing intervals

Blepharospasm minimum age>= 18 years

Cervical dystonia minimum age>= 18 years

Sialorrhea minimum age>= 2 years

Upper limb spasticity minimum age>= 2 years

Blepharospasm dosing intervalNot more frequently than once every 12 weeks

Cervical dystonia dosing intervalNot more frequently than once every 12 weeks

Sialorrhea dosing intervalNot more frequently than once every 16 weeks

Upper limb spasticity dosing intervalNot more frequently than once every 12 weeks

Cervical dystonia maximum dose240 units (initial dose not to exceed 120 units)

Upper limb spasticity maximum dose (adult)400 units

Sialorrhea maximum dose (adult)100 units

Clinical and Policy Background

Xeomin (incobotulinumtoxinA) is a botulinum toxin product that acts as an acetylcholine release inhibitor and neuromuscular‑blocking agent and is indicated for the treatment of blepharospasm (adults), cervical dystonia (adults), chronic sialorrhea (patients ≥ 2 years), and upper limb spasticity (adults and pediatric patients ≥ 2 years) in alignment with the FDA‑approved prescribing information.

This coverage policy requires Prior Authorization for benefit coverage of Xeomin; approvals are recommended only when the documented clinical criteria and dosing limits in the policy are met, and extended approvals may be granted if the patient continues to meet criteria. Documentation (e.g., chart notes) is specifically required for blepharospasm (evidence of involuntary orbicularis oculi contractions) and for cervical dystonia (diagnosis plus sustained head torsion/tilt with limited neck range of motion). Requests for doses outside the policy dosing will be reviewed case‑by‑case by a clinician (Medical Director or Pharmacist).

Dosing and administration limits are specified by indication. For blepharospasm the maximum approved dose is 100 units (50 units per eye), administered no more frequently than once every 12 weeks. For cervical dystonia the policy specifies a maximum of 240 units with the initial dose not to exceed 120 units, administered no more frequently than once every 12 weeks. For chronic sialorrhea adults the maximum is 100 units (50 units per side) and pediatric patients <18 years may receive up to 75 units (37.5 units per side), with dosing intervals of not more frequently than every 16 weeks. For upper limb spasticity adults the maximum is 400 units (pediatrics <18 years: 16 units/kg, not to exceed 400 units), with dosing intervals of not more frequently than every 12 weeks.

Providers authorizing or administering Xeomin should follow the coding and procedure guidance in the policy (e.g., CPT codes such as 64612, 64616, 64611, 64642‑64647 as applicable, and HCPCS J0588 for incobotulinumtoxinA units). The policy also clarifies that Xeomin is not recommended for coverage for cosmetic uses and that this is a new policy with a material dosing update to cervical dystonia implemented in the 2025 annual revision.

Approvals and coverage determinations remain subject to the member’s specific benefit plan terms and applicable laws; medical directors are expected to exercise clinical judgment for individual cases and to review requests for nonstandard dosing on a case‑by‑case basis.

OpenPayer

Xeomin (incobotulinumtoxinA) coverage

Medical Necessity Criteria

Relevant CPT / HCPCS Codes

What Providers Must Do

Quick Reference: Age, Dose, and Interval Limits

Clinical and Policy Background

Defined Terms

Policy Changes